MLTX Stock Forecast 2025-2026
Distance to MLTX Price Targets
MLTX Price Momentum
10 Quality Stocks Worth Considering Now
Researching MoonLake (MLTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MLTX and similar high-potential opportunities.
Latest MLTX Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, MLTX has a bullish consensus with a median price target of $75.00 (ranging from $65.00 to $104.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $38.33, the median forecast implies a 95.7% upside. This outlook is supported by 15 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andreas Argyrides at Oppenheimer, projecting a 171.4% upside. Conversely, the most conservative target is provided by Prakhar Agrawal at Cantor Fitzgerald, suggesting a 69.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MLTX Analyst Ratings
MLTX Price Target Range
Latest MLTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MLTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 18, 2025 | RBC Capital | Brian Abrahams | Outperform | Initiates | $67.00 |
| Feb 27, 2025 | Needham | Serge Belanger | Buy | Maintains | $66.00 |
| Feb 27, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Feb 27, 2025 | Goldman Sachs | Richard Law | Buy | Maintains | $73.00 |
| Jan 17, 2025 | Goldman Sachs | Richard Law | Buy | Upgrade | $82.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Nov 5, 2024 | Wedbush | Yun Zhong | Outperform | Assumes | $73.00 |
| Oct 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Sep 23, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Reiterates | $0.00 |
| Sep 12, 2024 | Needham | Serge Belanger | Buy | Reiterates | $62.00 |
| Sep 12, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Reiterates | $0.00 |
| Aug 26, 2024 | Wolfe Research | Andy Chen | Peer Perform | Downgrade | $0.00 |
| Aug 8, 2024 | Needham | Serge Belanger | Buy | Maintains | $62.00 |
| Jul 1, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Jun 25, 2024 | Oppenheimer | Andreas Argyrides | Outperform | Initiates | $104.00 |
| Jun 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Jun 10, 2024 | Needham | Serge Belanger | Buy | Reiterates | $66.00 |
MoonLake Immunotherapeutics (MLTX) Competitors
The following stocks are similar to MoonLake based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MoonLake Immunotherapeutics (MLTX) Financial Data
MoonLake Immunotherapeutics has a market capitalization of $2.43B with a P/E ratio of -20.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -25.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
MoonLake Immunotherapeutics (MLTX) Business Model
About MoonLake Immunotherapeutics
Develops treatments for inflammatory conditions.
MoonLake Immunotherapeutics generates revenue by developing next-generation nanobody therapeutics that target inflammatory diseases. The company focuses on conditions like hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis, aiming to enhance treatment efficacy and patient outcomes through its innovative Sonelokimab technology.
The company collaborates with global research institutions to advance its therapeutic approaches and address unmet medical needs. MoonLake's commitment to improving patient quality of life positions it as a significant player in the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
100
CEO
Dr. Jorge Santos da Silva Ph.D.
Country
Switzerland
IPO Year
2020
Website
www.moonlaketx.comMoonLake Immunotherapeutics (MLTX) Latest News & Analysis
MoonLake Immunotherapeutics: A Buy At Dips
11 days agoMoonLake Immunotherapeutics' sonelokimab outperformed competitors in trials but faced a stock drop due to institutional sell-offs. Despite mixed ARGO study results, it showed strong efficacy. The company has a cash runway into 2027.
MoonLake's sonelokimab shows promising efficacy, but institutional sell-offs led to stock declines. Financial stability and potential for future success could attract long-term investors.
MoonLake Immunotherapeutics has secured up to $500 million in non-dilutive financing from Hercules Capital, with $75 million available immediately and further tranches contingent on milestones.
MoonLake's $500 million non-dilutive financing boosts its capital for R&D, potentially accelerating product development and enhancing investor confidence in future growth.
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
1 month agoMoonLake Immunotherapeutics (NASDAQ: MLTX) reported its financial results for Q4 and the year ending December 31, 2024, focusing on therapies for inflammatory skin and joint diseases.
The financial results of MoonLake Immunotherapeutics can impact investor sentiment and stock performance, reflecting the company's growth potential and market position in the biotech sector.
MoonLake Immunotherapeutics will release phase 3 VELA-1 and VELA-2 study results for sonelokimab in mid-2025, which may support a BLA filing if positive, potentially boosting shareholder value.
Positive results from MoonLake's VELA studies could position sonelokimab as a leading treatment, potentially boosting market valuation and impacting investor sentiment significantly.
MoonLake Immunotherapeutics has initiated three new trials for sonelokimab, targeting adolescent hidradenitis suppurativa, palmoplantar pustulosis, and axial spondyloarthritis, expanding its clinical program. Data read-outs are expected in 2025 and 2026.
The initiation of new clinical trials for sonelokimab expands MoonLake's pipeline, potentially increasing future revenue and market presence in inflammatory disease treatments, impacting stock valuation.
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
7 months agoMoonLake Immunotherapeutics will host a Capital Markets Update on September 11, 2024, focusing on business updates and Phase 3 programs for sonelokimab in hidradenitis suppurativa and psoriatic arthritis.
MoonLake's Capital Markets Update will reveal key insights on their drug development progress and pipeline, impacting future stock performance and investor sentiment.
Frequently Asked Questions About MLTX Stock
What is MoonLake Immunotherapeutics's (MLTX) stock forecast for 2025?
Based on our analysis of 16 Wall Street analysts, MoonLake Immunotherapeutics (MLTX) has a median price target of $75.00. The highest price target is $104.00 and the lowest is $65.00.
Is MLTX stock a good investment in 2025?
According to current analyst ratings, MLTX has 15 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $38.33. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MLTX stock?
Wall Street analysts predict MLTX stock could reach $75.00 in the next 12 months. This represents a 95.7% increase from the current price of $38.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MoonLake Immunotherapeutics's business model?
MoonLake Immunotherapeutics generates revenue by developing next-generation nanobody therapeutics that target inflammatory diseases. The company focuses on conditions like hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis, aiming to enhance treatment efficacy and patient outcomes through its innovative Sonelokimab technology.
What is the highest forecasted price for MLTX MoonLake Immunotherapeutics?
The highest price target for MLTX is $104.00 from Andreas Argyrides at Oppenheimer, which represents a 171.4% increase from the current price of $38.33.
What is the lowest forecasted price for MLTX MoonLake Immunotherapeutics?
The lowest price target for MLTX is $65.00 from Prakhar Agrawal at Cantor Fitzgerald, which represents a 69.6% increase from the current price of $38.33.
What is the overall MLTX consensus from analysts for MoonLake Immunotherapeutics?
The overall analyst consensus for MLTX is bullish. Out of 16 Wall Street analysts, 15 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $75.00.
How accurate are MLTX stock price projections?
Stock price projections, including those for MoonLake Immunotherapeutics, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.